

Updated COVID-19 Vaccines

Joseph Crump BSN, RN
COVID-19 Vaccine Provider Education Coordinator
Nevada State Immunization Program

10/25/2023



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

ALL IN GOOD HEALTH.



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

ABOUT

DRBHS

to promote, and improve the physical and behavioral health and safety of all Nevada, equitably and regardless of circumstances, so they can live their safest, longest, healthiest, and happiest life.

VISION

A Nevada where preventable health and safety issues no longer impact the opportunity for all people to live life in the best possible health.

MISSION

To make everyone's life healthier, happier, longer, and safer.

VALUES

GOALS



ALL IN GOOD HEALTH.

AGENDA

- 1.** Available Vaccine Presentations
- 2.** Storage and Handling
- 3.** Dosing and Administration Schedule
- 4.** Vaccine Coadministration
- 5.** Vaccine Interchangeability
- 6.** Transitioning Age Groups Between Doses
- 7.** Vaccine Risks

Available Vaccine Presentations



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- mRNA vaccines
 - Updated monovalent vaccines are based on the Omicron XBB.1.5 sublineage.
 - Includes:
 - Moderna COVID-19 mRNA vaccine (2023-2024 formula)
 - SPIKEVAX
 - Pfizer-BioNTech COVID-19 mRNA vaccine (2023-2024 formula)
 - COMIRNATY
- Protein subunit vaccine
 - Updated monovalent vaccines are based on the Omicron XBB.1.5 sublineage.
 - Includes:
 - Novavax COVID-19 vaccine, adjuvanted (2023-2024 FORMULA)

Available Vaccine Presentations 6 months-4 years



NEVADA DIVISION of PUBLIC and BEHAVIORAL HEALTH

- Pfizer BioNTech Monovalent COVID-19 Vaccine (2023-2024 Formula)
 - Yellow cap vial
 - Must be Diluted with 1.1 mL Sterile 0.9% Sodium Chloride Injection
 - Multi-dose vial: 3 doses per vial
 - 3mcg/ 0.3mL dose

- Moderna Monovalent COVID-19 Vaccine (2023-2024 Formula)
 - Blue cap vial, Green label
 - Single Dose Vial
 - 25 mcg/ 0.25mL dose



Multidose Vial
(Contains 3 doses)
YELLOW cap and label
with YELLOW border
DILUTE PRIOR TO USE

Single dose vial with a dark blue cap and a label with a green box



[SRL-%20SPIKEVAX%20\(2023-2024%20Formula\)%20and%20Moderna%20COVID-19%20Vaccine%202023-2024%20Formula%20Dosage,%20Preparation%20and%20Administration_CLEAN.pdf](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html)

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

<file:///C:/Users/jcrump/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/7VRFLDCQ/PP-CVV-USA-2739.pdf>

Available Vaccine Presentations 5-11 years



- Pfizer BioNTech Monovalent COVID-19 Vaccine (2023-2024 Formula)
 - Blue cap vial
 - Do NOT dilute
 - Single dose vial
 - 10 mcg/ 0.3mL dose
- Moderna Monovalent COVID-19 Vaccine (2023-2024 Formula)
 - Blue cap vial, Green label
 - Single Dose Vial
 - 25 mcg/ 0.25mL dose



Single Dose Vial
BLUE cap and label
with BLUE border
DO NOT DILUTE

Single dose vial with a **dark blue cap** and a **label with a green box**



[SRL-%20SPIKEVAX%20\(2023-2024%20Formula\)%20and%20Moderna%20COVID-19%20Vaccine%202023-2024%20Formula%20Dosage,%20Preparation%20and%20Administration_CLEAN.pdf](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html)

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

<file:///C:/Users/jcrump/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/7VRFLDCQ/PP-CVV-USA-2739.pdf>

Available Vaccine Presentations 12 years and older



NEVADA DIVISION of PUBLIC and BEHAVIORAL HEALTH

Comirnaty Monovalent COVID-19 Vaccine (2023-2024 Formula)

- Gray cap vial
 - Do NOT dilute
 - Single dose vial
 - 30mcg/ 0.3mL dose
- Single dose prefilled syringe*
- 30mcg/ 0.3mL dose

Only available through private purchase



Single Dose Vial
GRAY cap and label with GRAY border
DO NOT DILUTE

or


Single Dose Prefilled Syringe



Spikevax Monovalent COVID-19 Vaccine (2023-2024 Formula)

- Blue cap vial, blue label
- Single Dose Vial
- 50 mcg/ 0.5mL dose

Single dose vial with a dark blue cap and a label with a blue box



[SRL-%20SPIKEVAX%20\(2023-2024%20Formula\)%20and%20Moderna%20COVID-19%20Vaccine%202023-2024%20Formula%20Dosage,%20Preparation%20and%20Administration_CLEAN.pdf](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html)

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

<file:///C:/Users/jcrump/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/7VRFLDCQ/PP-CVV-USA-2739.pdf>

Available Vaccine Presentations 12 years and older Continued



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- NOVAVAX COVID-19 VACCINE, ADJUVANTED (2023-2024 FORMULA)
 - Multi dose vial: can have 5 doses
 - 0.5 mL dose

Vaccine Storage and Handling



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- Pfizer BioNTech Monovalent COVID-19 Vaccine (2023-2024 Formula)
 - Frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76 °F) until the expiration date printed on the vials and cartons.
 - Once received, frozen vials may be immediately transferred to the refrigerator [2°C to 8°C (35°F to 46°F)], thawed and stored for up to 10 weeks, not to exceed the expiration date printed on the vial and cartons.
 - Cartons of multiple dose vials with yellow caps and labels with yellow borders and cartons of single dose vials with blue caps and labels with blue borders may take up to 2 hours to thaw at this temperature
 - Do NOT refreeze vials
 - Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) may be stored at room temperature [8°C to 25°C (46°F to 77°F)] for a total of 12 hours prior to the first puncture. After dilution (yellow cap only), multiple dose vials should be held between 2°C to 25°C (35°F to 77°F). Multiple dose vials should be discarded 12 hours after dilution.

Vaccine Storage and Handling Continued



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Moderna Monovalent COVID-19 Vaccine (2023-2024 Formula)

- Frozen Storage
 - Store frozen between -50°C to -15°C (-58°F to 5°F).
- Storage after Thawing
 - Storage at 2°C to 8°C (36°F to 46°F):
 - Vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to first use.
 - Vials should be discarded after single use.
 - Storage at 8°C to 25°C (46°F to 77°F):
 - Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.
 - Vials should be discarded after single use.
 - Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours.

Vaccine Storage and Handling Continued



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- Comirnaty Monovalent COVID-19 Vaccine (2023-2024 Formula)
 - Frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F) until the expiration date printed on the vials and cartons.
 - Once received, frozen vials may be immediately transferred to the refrigerator [2°C to 8°C (35°F to 46°F)], thawed and stored for up to 10 weeks, not to exceed the expiration date printed on the vial and cartons.
 - If cartons of COMIRNATY single dose vials and prefilled syringes are received at 2°C to 8°C (35°F to 46°F), they should be stored at 2°C to 8°C (35°F to 46°F)

Vaccine Storage and Handling Continued



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Spikevax Monovalent COVID-19 Vaccine (2023-2024 Formula)

- Frozen Storage
 - Store frozen between -50°C to -15°C (-58°F to 5°F).
- Storage after Thawing
 - Storage at 2°C to 8°C (36°F to 46°F):
 - Vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to first use.
 - Vials should be discarded after single use.
 - Storage at 8°C to 25°C (46°F to 77°F):
 - Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.
 - Vials should be discarded after single use.
 - Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours.

Vaccine Storage and Handling Continued



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Updated Novavax COVID-19 Vaccine, Adjuvanted

- Store the unpunctured multi-dose vial in a refrigerator between 2 to 8° C (36 to 46°F).
- After the first needle puncture, hold the vial between 2 to 25°C (36 to 77°F) for up to 12 hours. Discard the vial 12 hours after the first puncture.

Non-immunocompromised Dosing and Administration Schedule



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Ages 6 months–4 years

COVID-19 vaccination history prior to updated (2023–2024 Formula) mRNA vaccine*	Updated (2023–2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA vaccine doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna	2	0.25 mL/25 ug	Dark blue cap; green label	Dose 1 and Dose 2: 4–8 weeks [†]
	Pfizer-BioNTech	3	0.3 mL/3 ug	Yellow cap; yellow label	Dose 1 and Dose 2: 3–8 weeks [†] Dose 2 and Dose 3: At least 8 weeks
1 dose any Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; green label	4–8 weeks after last dose [†]
2 or more doses any Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; green label	At least 8 weeks after last dose

Non-immunocompromised Dosing and Administration Schedule Continued



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Ages 6 months–4 years

1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/3 ug	Yellow cap; yellow label	Dose 1: 3–8 weeks after last dose* Dose 1 and Dose 2: At least 8 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	Yellow cap; yellow label	At least 8 weeks after last dose
3 or more doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	Yellow cap; yellow label	At least 8 weeks after last dose

Non-immunocompromised Dosing and Administration Schedule Cont.



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Ages 5–11 years[†]

COVID-19 vaccination history prior to updated (2023–2024 Formula) mRNA vaccine*	Updated (2023–2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna	1	0.25 mL/25 ug	Dark blue cap; green label	—
	Pfizer-BioNTech	1	0.3 mL/10 ug	Blue cap; blue label	—
1 or more doses any mRNA	Moderna OR	1	0.25 mL/25 ug	Dark blue cap; green label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/10 ug	Blue cap; blue label	At least 8 weeks after last dose

Non-immunocompromised Dosing and Administration Schedule Cont.

Ages 12 years and older



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

COVID-19 vaccination history prior to updated (2023–2024 Formula) mRNA vaccine*	Updated (2023–2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA doses indicated	Dosage (mL/ug)	Vaccine vial cap and label colors [§]	Interval between doses
Unvaccinated	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	—
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	—
1 or more doses any mRNA	Moderna OR	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose
1 or more doses Novavax or Janssen, including in combination with any mRNA vaccine dose(s)	Moderna OR	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose

Immunocompromised Dosing and Administration Schedule Cont.

Ages 6 months–4 years



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

COVID-19 vaccination history prior to updated (2023–2024 Formula) mRNA vaccine*	Updated (2023–2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA doses indicated†	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna	3	0.25 mL/25 ug	Dark blue cap; green label	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	Pfizer-BioNTech	3	0.3 mL/3 ug	Yellow cap; yellow label	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 8 weeks
1 dose any Moderna	Moderna	2	0.25 mL/25 ug	Dark blue cap; green label	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; green label	At least 4 weeks after last dose
3 or more doses any Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; green label	At least 8 weeks after last dose

Immunocompromised Dosing and Administration Schedule Cont.



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Ages 6 months–4 years

1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/3 ug	Yellow cap; yellow label	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 8 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	Yellow cap; yellow label	At least 8 weeks after last dose
3 or more doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	Yellow cap; yellow label	At least 8 weeks after last dose

Immunocompromised Dosing and Administration Schedule

Co Ages 5–11 years*



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine [†]	Updated (2023–2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA doses indicated [†]	Dosage (mL/ug)	Vaccine vial cap and label colors	Interval between doses
Unvaccinated	Moderna	3	0.25 mL/25 ug	Dark blue cap; green label	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	Pfizer-BioNTech	3	0.3 mL/10 ug	Blue cap; blue label	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 4 weeks
1 dose any Moderna	Moderna	2	0.25 mL/25 ug	Dark blue cap; green label	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.25 mL/25 ug	Dark blue cap; green label	At least 4 weeks after last dose

Immunocompromised Dosing and Administration Schedule Cont.



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

Ages 5–11 years*

1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/10 ug	Blue cap; blue label	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/10 ug	Blue cap; blue label	At least 4 weeks after last dose
3 or more doses any mRNA vaccine	Moderna OR	1	0.25 mL/25 ug	Dark blue cap; green label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/10 ug	Blue cap; blue label	At least 8 weeks after last dose

Immunocompromised Dosing and Administration Schedule

Co¹ Ages 12 years and older*



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

COVID-19 vaccination history prior to updated (2023–2024 Formula) vaccine [†]	Updated (2023–2024 Formula) mRNA vaccine	Number of updated (2023–2024 Formula) mRNA doses indicated [‡]	Dosage (mL/ug)	Vaccine vial cap and label colors [§]	Interval between doses
Unvaccinated	Moderna	3	0.5 mL/50 ug	Dark blue cap; blue label	Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks
	Pfizer-BioNTech	3	0.3 mL/30 ug	Gray cap; gray label	Dose 1 and Dose 2: 3 weeks Dose 2 and Dose 3: At least 4 weeks
1 dose any Moderna	Moderna	2	0.5 mL/50 ug	Dark blue cap; blue label	Dose 1: 4 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Moderna	Moderna	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 4 weeks after last dose

Immunocompromised Dosing and Administration Schedule Cont.

Ages 12 years and older*



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/30 ug	Gray cap; gray label	Dose 1: 3 weeks after last dose Dose 1 and Dose 2: At least 4 weeks
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 4 weeks after last dose
3 or more doses any mRNA vaccine	Moderna OR	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose
1 or more doses of Novavax or Janssen, including in combination with any mRNA vaccine dose(s)	Moderna OR	1	0.5 mL/50 ug	Dark blue cap; blue label	At least 8 weeks after last dose
	Pfizer-BioNTech	1	0.3 mL/30 ug	Gray cap; gray label	At least 8 weeks after last dose

Dosing and Administration for NOVAVAX COVID-19 VACCINE, ADJUVANTED (2023-2024 FORMULA)



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- Individuals 12 years and older who have been previously vaccinated with a COVID-19 vaccine (but not vaccinated with an updated mRNA COVID-19 vaccine) are eligible to receive 1, 0.5 mL dose of an updated Novavax COVID-19 vaccine at least 2 months after their last dose.
- Individuals 12 years and older who are unvaccinated for COVID-19 are eligible to receive a 2-dose series of updated Novavax COVID-19 vaccine, with doses at least 3 weeks apart.
- The previous, original presentation of Novavax COVID-19 vaccine is now no longer authorized for emergency use in the United States.

Vaccine Coadministration



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- In accordance with [General Best Practice Guidelines for Immunization](#), routine administration of all age-appropriate doses of vaccines simultaneously, also known as coadministration, is recommended for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit.
 - Providers may simultaneously administer COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines to eligible patients
 - Coadministration of vaccines should be at different anatomic sites, and not combined in the same syringe

Vaccine

Interchangeability



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- Children ages 6 months–4 years should receive all doses of COVID-19 vaccine from the same manufacturer; this includes children who are moderately or severely immunocompromised and those who are not. People ages 5 years and older who are moderately or severely immunocompromised should receive a 3-dose initial vaccination series using vaccines from the same manufacturer.
- In the following exceptional situations, a different age-appropriate COVID-19 vaccine may be administered:
 - Same vaccine not available
 - Previous dose unknown
 - Person would otherwise not complete the vaccination series
 - Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

Transitioning to an Older Age Group



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- In general, CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination.
- If a person moves to an older age group between vaccine doses, they should receive the vaccine product and dosage for the older age group for all subsequent doses with one exception:
 - The FDA EUA provides that children who transition from age 4 years to age 5 years during the Pfizer-BioNTech COVID-19 vaccination series complete the 3-dose series with updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine for ages 6 months–4 years, 0.3 mL/3 ug (yellow cap; yellow label).
- In addition, the FDA EUA provides that children who transition from age 4 years to age 5 years during the Moderna vaccination series complete the 2-dose series; there is no dosage change.

Vaccine Risks: Myocarditis and Pericarditis



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- Although cases are rare, they have occurred most frequently in adolescent and young adult males within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (Moderna and Pfizer-BioNTech); however, cases have also been observed in females and after other doses.
- People receiving any COVID-19 vaccine, especially males ages 12–39 years, should be made aware of the rare risk of myocarditis and pericarditis following COVID-19 vaccination.
- An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

Helpful Resources!



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

- <https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf>
- <https://www.cdc.gov/vaccines/covid-19/downloads/COVID19-vaccination-recommendations-most-people.pdf>
- <https://www.cdc.gov/vaccines/covid-19/downloads/COVID19-vaccination-recommendations-immunocompromised.pdf>
- <https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>
- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b:~:text=Appendix%20A.%20People%20who%20received%20COVID%2D19%20vaccine%20outside%20the%20United%20States>
- <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b:~:text=Appendix%20B.%20Vaccine%20administration%20errors%20and%20deviations>

QUESTI --- ONS?



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH



NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH

CONTACT INFORMATI

Joseph Crump BSN,RN
COVID-19 Vaccine Provider education
Coordinator
ON
jcrump@health.nv.gov

Nevada Division of Public and Behavioral Health
4150 Technology Way, Carson City, NV 89706
Phone: 775-684-4200 | FAX: 775-687-7570
Email: dpbh@health.nv.gov

ACRONYMS

CDC: Centers for Disease Control and Prevention

FDA: Food and Drug Administration

EUA: Emergency Use Authorization

Mcg/ug: microgram

mL: milliliter



**NEVADA DIVISION of PUBLIC
and BEHAVIORAL HEALTH**